Ablation Techniques for Lung Nodules: Percutaneous or Transbronchial Approach?
Tsukasa Ishiwata+more
Surgical resection is the most effective treatment for patients with early-stage NSCLC.1 However, approximately 25% of these patients do not undergo resection, usually because of underlying comorbidities precluding surgery or […] Read more
June 23, 2021—Savolitinib was approved in China for treatment of patients with NSCLC with MET exon 14 skipping alterations whose disease has progressed following systemic treatment or who are […] Read more
July 19—The National Medical Products Administration in China approved durvalumab in combination with standard-of-care platinum chemotherapy (as defined as etoposide plus carboplatin or cisplatin) for the first-line management of extensive-stage […] Read more
Dr. Patrick Forde Discusses Excitement Around Neoadjuvant Immunotherapy for Lung Cancer
Patrick FordeCheckMate-816 made quite a splash at both the AACR Annual Meeting 2021 and the 2021 ASCO Annual Meeting’s virtual podium, and the accompanying article by Patrick Forde, MD, explains why. Dr. Forde, who is director of the Thoracic Oncology Clinical Research Program and associate professor of Oncology at Johns Hopkins... Read more
Addition of Nivolumab to Neoadjuvant Chemotherapy in NSCLC: Results of CheckMate-816
Patrick FordePlatinum-based chemotherapy, given either before (neoadjuvant) or after (adjuvant) surgery for stage II and III NSCLC is associated with a 5% improvement in long-term survival. Despite consensus guidelines recommending its […] Read more
Veterans Health Administration’s Lung Precision Oncology Program Helps Individualize Treatment
Michael Kelley+more
Lung cancer is not only the leading cause of cancer deaths in the United States, with nearly 229,000 people diagnosed annually, but is also the deadliest cancer affecting patients of […] Read more
A 65-year-old patient with stage III NSCLC comes to your clinic to discuss concurrent chemoradiotherapy. She has a history of ischemic heart disease, and 4 years ago an angiogram demonstrated […] Read more
Hippocampal-Sparing Brain Irradiation: The Future of Brain Metastases Treatment and Prevention?
Lizza Hendriks+more
Brain metastases (BMs) are frequently diagnosed in patients with SCLC and NSCLC, although the incidence is highest in SCLC.1 ,2 ,3 BMs are a negative prognostic factor and are associated […] Read more
Second-Line, Biomarker-Driven Therapies for Squamous NSCLC: Report on Lung-MAP SWOG S1400
Julia Judd+more
The Lung Master Protocol (Lung-MAP; S1400) was a biomarker-driven master protocol. This trial was originally designed to address the relative paucity of effective, targeted therapies in squamous cell lung cancer, […] Read more
America’s decades-long war on smoking has been remarkably successful in reducing smoking rates, but the unintended consequences include stigmatizing people who smoke and people with lung cancer. Sadly, those dealing […] Read more